With big-boy valuation, Moderna should stop acting like a penny stock

published 19.05.2020 12:59

Image of article 'With big-boy valuation, Moderna should stop acting like a penny stock'
Share

Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock Some additional thoughts and comments on Moderna, its coronavirus vaccine, the stock’s valuation and Monday night’s $1.3 billion stock sale: Of course, Moderna raised money.

It was only one week ago that I described Moderna’s $23 billion enterprise value as “astonishingly high” for a company with no approved products and no appreciable revenue.

Monday, it was $29 billion, with the stock reaching another all-time high of $80 per share, or four times the price from the beginning of the year.